rezpegaldesleukin — Topline data
Q4 2026
Topline data to be reported from the 24-week off-treatment period in REZOLVE-AA in Q4 2026.Source filing
NKTR biotech catalysts & pipeline
NEKTAR THERAPEUTICS · Data as of 2026-09-08
Upcoming catalysts
rezpegaldesleukin — Topline data
Q1 2027
Topline data to be reported from the 52-week off-treatment period in REZOLVE-AD in Q1 2027.Source filing
rezpegaldesleukin — Initial data
in 2027
Initial data from TrialNet sponsored Phase 2 study in Type 1 Diabetes in 2027Source filing
rezpegaldesleukin — Topline data
mid-2028
Our financial position is strong with over one billion dollars in cash and investments at the end of the quarter, and a cash runway that extends into the third quarter of 2028, past the initial Phase 3 data readouts expected in mid-2028.Source filing
rezpegaldesleukin — Regulatory decision
2029
Our Phase 3 program establishes a clear path to the first BLA submission for rezpegaldesleukin in 2029.Source filing
NKTR-0165 — Conference presentation
in H2 2026
Preclinical data presentation from the NKTR-0165 (TNFR2 agonist antibody) program at a scientific conference in H2 2026Source filing
rezpegaldesleukin — Conference presentation
Oct 1
Presentation Date and Time: Thursday, October 1 st 10:25 – 10:35 CESTSource filing